Radial Optic Neurotomy for Central Retinal Vein Occlusion — Cost, Top Hospitals & Success Rates | MyMedicPlus

Radial optic neurotomy (RON) is a vitreoretinal surgical procedure designed to relieve compression of the central retinal vein as it passes through the lamina cribrosa of the optic nerve head — the presumed anatomical site of obstruction in central retinal vein occlusion (CRVO). The procedure involves performing a pars plana vitrectomy and then making one or more radial incisions into the nasal aspect of the optic disc tissue to expand the compartment surrounding the central retinal vein.

CRVO is a major cause of sudden, painless vision loss affecting approximately 1–2 per 1,000 adults, with peak incidence after age 60. Risk factors include hypertension, diabetes, hyperlipidaemia, glaucoma, thrombophilia, and hyperviscosity states. It presents with widespread intraretinal haemorrhages in all four quadrants, retinal oedema, cotton-wool spots, and disc oedema. Macular oedema — swelling at the centre of the retina responsible for detailed vision — is the primary driver of chronic vision loss.

RON was introduced by Opremcak and colleagues in 2001 as a surgical alternative for patients with severe non-ischaemic CRVO who were not recovering spontaneously. The procedure generated significant early enthusiasm based on retrospective case series showing visual improvement in a majority of patients. However, subsequent controlled studies and the emergence of highly effective intravitreal pharmacotherapy (anti-VEGF agents, dexamethasone implants) have substantially reduced RON's role in contemporary practice.

Important note: RON remains a controversial and investigational procedure. It is not endorsed by major ophthalmological societies as a standard-of-care treatment for CRVO. Patients considering RON should be thoroughly counselled about the evidence limitations and the availability of safer, pharmacologically proven alternatives.

Radial optic neurotomy is specifically proposed for:

• Non-ischaemic central retinal vein occlusion (CRVO): CRVO characterised by preserved retinal perfusion (electroretinography showing normal b-wave amplitude), persistent macular oedema, and significant visual acuity loss (typically worse than 6/36) not improving after 3–6 months of observation or failed pharmacological treatment.
• Ischaemic CRVO (controversial and generally avoided): Some early case series included ischaemic cases, but the risk of accelerating neovascular complications (neovascular glaucoma, proliferative retinopathy) makes RON particularly hazardous in this subtype. Most vitreoretinal surgeons consider ischaemic CRVO a contraindication.

RON is not indicated for:

• Branch retinal vein occlusion (BRVO)
• CRVO responding to intravitreal pharmacotherapy
• Mild CRVO with good visual acuity
• Neovascular CRVO (high risk of complications)

The majority of CRVO cases today are managed medically with intravitreal anti-VEGF injections (ranibizumab, bevacizumab, aflibercept) or dexamethasone implants (Ozurdex), which are supported by robust evidence from large randomised controlled trials (CRUISE, HORIZON, GENEVA studies). RON is now rarely performed and should be considered only when pharmacological options have been exhausted or are unavailable.

In centres where RON is still offered, the proposed selection criteria include:

• Confirmed non-ischaemic CRVO: Fundus fluorescein angiography (FFA) confirming preserved retinal perfusion; electroretinography showing subnormal but present b-wave.
• Significant visual impairment: Best-corrected visual acuity worse than 6/36 (20/120) with macular oedema confirmed on optical coherence tomography (OCT).
• Duration of CRVO: Typically performed within 3–6 months of onset, before ischaemic conversion or irreversible macular damage occurs.
• Failed or unsuitable for pharmacotherapy: Intravitreal anti-VEGF injections or dexamethasone implants are first-line; RON might be considered when these are unavailable, contraindicated (e.g., pregnancy, uncontrolled glaucoma for steroid implant), or when multiple treatment cycles have failed.
• Systemic risk factors controlled: Hypertension, diabetes, and hyperlipidaemia should be optimally managed to prevent progression and improve vascular healing.
• Patient counselling: Patients must be fully informed of the experimental nature, limited evidence, and specific risks including permanent visual field defects before consenting.

Patients with neovascular CRVO, dense vitreous haemorrhage obscuring surgical view, or significant systemic illness precluding vitreoretinal surgery under general anaesthesia are not suitable candidates.

RON is performed as a vitreoretinal procedure under general anaesthesia (or retrobulbar block with monitored sedation):

Step 1: Pars Plana Vitrectomy

Standard 23- or 25-gauge three-port pars plana vitrectomy is performed to clear the vitreous gel, improve surgical visualisation, and allow instruments access to the posterior segment. Complete posterior vitreous detachment (PVD) is induced if not already present, as this may itself provide some benefit in CRVO by reducing traction on retinal vessels.

Step 2: Radial Incision at the Optic Disc

Using a microvitreoretinal (MVR) blade or a dedicated neurotomy instrument, a single radial incision is made at the nasal margin of the optic disc, extending 1–3 mm into the nerve tissue. The incision is directed radially (along a spoke-like path from the disc margin into surrounding nerve tissue) to expand the constrained fascial compartment surrounding the central retinal vein. Some surgeons make 2–3 incisions, though single incision is more common.

Step 3: Air or Gas Tamponade

The vitreous cavity may be filled with gas (sulfur hexafluoride SF6 or perfluoropropane C3F8) or air at the end of surgery to maintain intraocular pressure and reduce haemorrhagic risk, though this is variable by surgeon preference.

Step 4: Post-operative Management

Face-down positioning may be required for 1–5 days if gas is used. Visual field testing is performed at 6–8 weeks to document any new scotomas from optic nerve incision. Serial OCT macular imaging and visual acuity monitoring assess treatment response over 3–6 months.

Based on available case series and retrospective data (noting that no large randomised controlled trial has confirmed these outcomes):

• Visual acuity improvement: Observational studies report improvement in visual acuity in 60–80% of treated patients, with some achieving gain of 3 or more ETDRS lines over 6–12 months. However, this must be compared against the natural history of non-ischaemic CRVO, in which approximately 30–50% of patients experience spontaneous visual improvement.
• Macular oedema reduction: RON may facilitate resolution of cystoid macular oedema through decompression of venous drainage and development of chorioretinal anastomoses (new venous drainage channels bypassing the occluded vein).
• Chorioretinal anastomosis formation: A potentially beneficial mechanism: radial incisions may facilitate development of alternative venous drainage, reducing venous hypertension in the retina.
• Single procedure: Unlike anti-VEGF therapy requiring monthly or near-monthly injections, a single RON procedure may — if effective — provide sustained benefit without repeated interventions. This could be relevant in resource-limited settings.

Clinical caveat: These potential benefits have not been confirmed in a well-powered randomised controlled trial, and the procedure should not be presented to patients as established effective treatment.

RON carries significant surgical risks that are central to understanding why it is rarely recommended today:

• Visual field defects (10–30%): The most concerning complication. Incising the optic nerve tissue inevitably risks damage to nerve fibre bundles, resulting in paracentral or arcuate scotomas that may be permanent.
• Vitreous haemorrhage: Bleeding from the optic disc incision site is common; usually clears spontaneously but may require re-operation.
• Subretinal or sub-RPE haemorrhage: Extension of bleeding beneath the retina can cause permanent central visual loss.
• Endophthalmitis: Rare but catastrophic post-operative intraocular infection; risk inherent to any vitreoretinal surgery (~0.05%).
• Retinal detachment: Uncommon but recognised complication of vitrectomy.
• Choroidal neovascularisation: New vessel growth from the choroid through the incision site can cause subretinal membrane formation and further vision loss.
• Acceleration of neovascularisation: In cases with unrecognised ischaemia, surgical manipulation may worsen neovascular complications including neovascular glaucoma.
• Optic disc scarring: Permanent architectural changes to the optic nerve head from incision.
• General anaesthesia risks: Cardiovascular and respiratory complications associated with general anaesthesia in often older, comorbid patients.

Post-operative management following RON involves:

Immediate Post-Operative (Days 1–7)

If gas tamponade is used, face-down positioning is required for 1–5 days to prevent the gas bubble from contacting the lens. Topical antibiotic (e.g., moxifloxacin) and anti-inflammatory drops (e.g., prednisolone acetate) are prescribed 4 times daily. Intraocular pressure monitoring is performed, as the gas bubble can temporarily elevate IOP.

Early Recovery (Weeks 2–8)

Vision may temporarily worsen due to post-operative inflammation and resolving haemorrhage before any improvement is seen. OCT imaging at weeks 4–8 assesses macular oedema response. Visual field testing is performed at 6–8 weeks to document any field defects from the optic nerve incision.

Medium-Term Follow-Up (Months 3–6)

Assessment of visual acuity trajectory, OCT macular thickness, and fundus fluorescein angiography to evaluate perfusion status and chorioretinal anastomosis development. If macular oedema persists despite RON, rescue therapy with intravitreal anti-VEGF or dexamethasone implant is typically offered.

Long-Term Monitoring

All CRVO patients require long-term follow-up regardless of treatment, including blood pressure monitoring, fasting glucose, lipid profile, and coagulation screening. Annual ocular examination to detect delayed neovascular complications or fellow eye involvement.

Cost considerations for RON are affected by its limited availability and the availability of pharmacological alternatives:

• Procedure cost: As a vitreoretinal surgery requiring an operating theatre, surgical microscope, vitrectomy equipment, and specialised instruments, RON costs are broadly similar to standard pars plana vitrectomy: approximately USD 4,000–10,000 in the US (surgeon + facility + anaesthesia), significantly less in India (USD 800–2,000) or Thailand (USD 1,000–2,500) at accredited retinal surgery centres.
• Comparison with pharmacotherapy: Intravitreal anti-VEGF injections (ranibizumab, aflibercept) cost USD 1,500–2,000 per injection in the US, with many patients requiring 6–12 or more injections in the first year. The dexamethasone implant (Ozurdex) costs USD 1,000–2,000 per implant and lasts 3–6 months. The cumulative annual cost of pharmacotherapy often exceeds the one-time cost of RON, which is a factor occasionally cited by surgeons offering RON in resource-limited settings.
• Limited insurance coverage: Given the experimental status of RON, many insurers in developed countries do not cover the procedure unless specific criteria are met. Patients should obtain prior authorisation and confirm coverage explicitly.
• Medical tourism: Vitreoretinal expertise for RON is concentrated in a small number of specialised centres. Patients travelling internationally should ensure their centre has documented experience with the procedure and appropriate post-operative follow-up infrastructure.

The following are evidence-based, widely accepted alternatives for managing CRVO with macular oedema:

• Intravitreal anti-VEGF injections (first-line): Ranibizumab (Lucentis), bevacizumab (Avastin, off-label), and aflibercept (Eylea) reduce macular oedema by blocking vascular endothelial growth factor, the primary mediator of vascular permeability in CRVO. The CRUISE trial (ranibizumab) showed >3 line visual acuity gain in 48% of treated patients at 6 months vs. 16.9% on sham injection. Monthly or treat-and-extend regimens are required for 1–2 years in many patients.
• Intravitreal dexamethasone implant (Ozurdex): A biodegradable sustained-release implant providing 3–6 months of dexamethasone delivery. The GENEVA trial demonstrated significant improvement in visual acuity and macular thickness. Particularly useful in patients who cannot tolerate frequent injections. Risks include cataract progression and elevated intraocular pressure (managed with topical drops).
• Intravitreal triamcinolone acetonide: Off-label corticosteroid injection; shorter duration of action than Ozurdex but less expensive. Significant risk of IOP elevation and cataract.
• Observation: In milder non-ischaemic CRVO (VA better than 6/18), a period of careful observation is reasonable as 30–50% of patients improve spontaneously. Monthly monitoring with OCT and VA testing is required.
• Laser photocoagulation: Panretinal photocoagulation (PRP) is used to treat neovascularisation in ischaemic CRVO to prevent neovascular glaucoma. It does not improve macular oedema or central vision and is specifically a prophylactic measure.
• Systemic risk factor management: Optimising hypertension, diabetes, and dyslipidaemia control reduces the risk of CRVO progression and fellow eye involvement.